It hasn’t been a great end to the week for the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO). In afternoon trade the benchmark index is down 0.7% to 5,459 points with declines being seen across every sector.

There have been four shares in particular which have stood out with sharp declines today. Here’s why:

Bellamy’s Australia Ltd (ASX: BAL) shares have fallen a stunning 38% to $7.50 following the release of a business update which revealed a “temporary volume dislocation due to regulatory changeover”. According to the release the Chinese market has been flooded with increasing supply as competitors look to offload their products which are unlikely to satisfy proposed tougher regulatory requirements. Elsewhere, a2 Milk Company Ltd (Australia) (ASX: A2M) shares are also lower despite its recent positive trading update.

BWX Ltd (ASX: BWX) shares are down 6% to $3.96 despite no news out of the company. It appears as though investors are concerned that this skincare company’s exports to China may also be impacted by the regulatory changes in China. I believe that this sell off makes BWX a buy. The company’s Sukin product has just launched in the UK, which could offset any potential decline in sales in China.

Catapult Group International Ltd (ASX: CAT) shares have plunged 8% to $2.94 a day after the sports analytics company released its FY 2017 revenue guidance. This year Catapult expects revenue to come in between $61 million and $65.5 million, representing pro-forma annual growth of 21% to 30%. Pleasingly the company also expects to deliver positive underlying EBITDA. Catapult is yet another company that I feel looks good value following a sell off today.

ResMed Inc. (CHESS) (ASX: RMD) shares are down over 3% to $8.04 after it emerged that the District Court in Munich had overturned both preliminary injunctions previously granted to the company against rival Fisher & Paykel Healthcare Corp Ltd (ASX: FPH). In August Fisher & Paykel was forced to stop selling the F&P Simplus, Eson and Eson 2 masks in Germany, but sales can recommence following the court’s decision. Fisher & Paykel’s shares have rallied on the news.

If your portfolio took a hit today don't worry. The smart money is on these hot stocks being big winners in 2017. Is yours?

Big, Fat, Dividends

This company's dividend is almost the stuff of legends. Its reliable cash flows support a high payout ratio, and the company's stash of franking credits are the cherry on the top of the dividend cake. Based on the last 12-months of dividends, shares are offering a fully-franked 6.5% yield, which grosses up to a whopping 9.3%, when those franking credits are included.

Discover out the name of this blue chip share along with 2 others in our new FREE report "The Motley Fool's Top 3 Blue Chips Stocks For 2017."

Click here to receive your copy.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia owns shares of A2 Milk, Bellamy's Australia, and BWX Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.